127 related articles for article (PubMed ID: 38044119)
1. Generic selection criteria for safety and patient benefit [Ⅻ]: Comparing the physicochemical and pharmaceutical properties of brand-name and generic tulobuterol tape.
Shimokawa KI; Yotsukura K; Nozawa M; Wada Y; Ishii F
Drug Discov Ther; 2024 Jan; 17(6):409-414. PubMed ID: 38044119
[TBL] [Abstract][Full Text] [Related]
2. Generic selection criteria for safety and patient benefit [VIII]: Comparing the physicochemical and pharmaceutical properties of brand-name and generic diclofenac sodium tapes.
Nozawa M; Goto M; Wada Y; Yotsukura K; Gannichida A; Ishii F; Shimokawa KI
Drug Discov Ther; 2019 Jul; 13(3):150-156. PubMed ID: 31257355
[TBL] [Abstract][Full Text] [Related]
3. Generic selection criteria for safety and patient benefit [X]: Water-vapor permeability and peel force properties of brand-name and generic ketoprofen tapes.
Nozawa M; Goto M; Wada Y; Ishii F; Shimokawa KI
Drug Discov Ther; 2021 May; 15(2):87-92. PubMed ID: 33952778
[TBL] [Abstract][Full Text] [Related]
4. [Questionnaire survey on the change of asthmatic response, adverse events and product usability due to drug switching between name-brand and generic tulobuterol tapes].
Izumi T; Hori S; Satoh H; Miki A; Sawada Y
Yakugaku Zasshi; 2012; 132(5):617-27. PubMed ID: 22687698
[TBL] [Abstract][Full Text] [Related]
5. Skin permeability of tulobuterol in two transdermal formulations and their followability.
Takizawa Y; Goto T; Sato S; Ohmori N; Mori K; Shimada Y; Chen K; Miyagi T; Fukai F
Drug Discov Ther; 2017 Nov; 11(5):253-258. PubMed ID: 29021505
[TBL] [Abstract][Full Text] [Related]
6. Generic selection criteria for safety and patient benefit [XI]: Usability scores of brand-name and generic tapes containing sodium diclofenac by questionnaire survey.
Nozawa M; Gannichida A; Wada Y; Kumazawa M; Ishii F; Shimokawa KI
Drug Discov Ther; 2022 Nov; 16(5):210-216. PubMed ID: 36261340
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of Adhesive Properties of Transdermal Patches Distributing in Japan-Tack and Peel Strength].
Miyazaki T; Kanno H; Aso Y; Goda Y
Yakugaku Zasshi; 2018 Nov; 138(11):1425-1433. PubMed ID: 30146539
[TBL] [Abstract][Full Text] [Related]
8. Generic Selection Criteria for Safety and Patient Benefit [IV] - Physicochemical and pharmaceutical properties of brand-name and generic ketoprofen tapes.
Wada Y; Kihara M; Nozawa M; Shimokawa K; Ishii F
Drug Discov Ther; 2015 Jun; 9(3):229-33. PubMed ID: 26193946
[TBL] [Abstract][Full Text] [Related]
9. [Model analysis of tulobuterol patch formulations to explain the influence of drug release rate and transdermal transfer rate on the plasma concentration profile].
Watanabe T; Satoh H; Hori S; Miki A; Ohtani H; Sawada Y
Yakugaku Zasshi; 2011; 131(10):1483-92. PubMed ID: 21963976
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of skin permeation profiles between brand and generic tulobuterol patches.
Yoshihara S; Fukuda H; Abe T; Arisaka O
Biol Pharm Bull; 2010; 33(10):1763-5. PubMed ID: 20930390
[TBL] [Abstract][Full Text] [Related]
11. Generic selection criteria for safety and patient benefit [VI]: Comparing the physicochemical and pharmaceutical properties of brand-name, generic, and OTC felbinac tapes.
Wada Y; Takaoka Y; Nozawa M; Goto M; Shimokawa KI; Ishii F
Drug Discov Ther; 2017 Jan; 10(6):300-306. PubMed ID: 27725574
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy and safety of transdermal tulobuterol in the treatment of stable COPD: an open-label comparison with inhaled salmeterol.
Fukuchi Y; Nagai A; Seyama K; Nishimura M; Hirata K; Kubo K; Ichinose M; Aizawa H;
Treat Respir Med; 2005; 4(6):447-55. PubMed ID: 16336029
[TBL] [Abstract][Full Text] [Related]
13. Generic selection criteria for safety and patient benefit [VII]: Comparing the physicochemical and pharmaceutical properties of brand-name and generic terbinafine hydrochloride cream.
Nozawa M; Goto M; Wada Y; Kumazawa M; Shimokawa KI; Ishii F
Drug Discov Ther; 2018 Mar; 12(1):16-20. PubMed ID: 29479048
[TBL] [Abstract][Full Text] [Related]
14. Bioequivalence assessment of tulobuterol transdermal delivery system in healthy subjects
.
Park SI; Kim BH
Int J Clin Pharmacol Ther; 2018 Aug; 56(8):381-386. PubMed ID: 29932416
[TBL] [Abstract][Full Text] [Related]
15. [Effect of Storage of Tulobuterol Tapes after Package Opening and Liner Peeling on Their Formulation Properties].
Iwanami A; Ota M; Hidaka S; Tajima M; Onishi H; Ikeuchi-Takahashi Y
Yakugaku Zasshi; 2021; 141(7):949-954. PubMed ID: 34193654
[TBL] [Abstract][Full Text] [Related]
16. [Questionnaire survey of patients comparing the usability of brand-name and generic ketoprofen tapes].
Saita A; Inoue A; Ishibashi H; Tominaga K; Hori S; Miki A; Ohtani H; Ono N; Sawada Y
Yakugaku Zasshi; 2008 May; 128(5):795-803. PubMed ID: 18451628
[TBL] [Abstract][Full Text] [Related]
17. [Effect of Adhesives on the Properties of Adhesion, Drug Release and Skin Permeation of Lidocaine Tapes].
Sugino M; Mikami M; Ishihara T; Hosoya O; Juni K
Yakugaku Zasshi; 2015; 135(8):977-85. PubMed ID: 26234356
[TBL] [Abstract][Full Text] [Related]
18. Generic selection criteria for safety and patient benefit [V]: Comparing the pharmaceutical properties and patient usability of original and generic nasal spray containing ketotifen fumarate.
Wada Y; Ami S; Nozawa M; Goto M; Shimokawa K; Ishii F
Drug Discov Ther; 2016; 10(2):88-92. PubMed ID: 27210891
[TBL] [Abstract][Full Text] [Related]
19. [Prediction of systemic exposure of ketoprofen tapes by in vitro release test and pharmacokinetic model analysis: comparison between brand-name and generic formulations].
Awa K; Satoh H; Hori S; Sawada Y
Yakugaku Zasshi; 2012; 132(1):135-44. PubMed ID: 22214588
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of a transdermal therapeutic system of the beta2-agonist tulobuterol in patients with mild or moderate persistent bronchial asthma.
Horiguchi T; Kondo R; Miyazaki J; Fukumokto K; Torigoe H
Arzneimittelforschung; 2004; 54(5):280-5. PubMed ID: 15212190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
